Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vortioxetine in major depressive disorder with early dementia
2019-001326-10Phase 4Completed
- Sponsor
- Lundbeck
- Start
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of vortioxetine in major depressive disorder (MDD), sponsored by Lundbeck. Primary endpoint: Change in Montgomery-Asberg Depression Rating Scale total score. Started Dec 2019; status: completed.
02
Drugs
vortioxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2019-001326-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001326-10.